Dr. Reddys Laboratories is currently trading at Rs. 3110.00, up by 18.50 points or 0.60% from its previous closing of Rs. 3091.50 on the BSE.
The scrip opened at Rs. 3115.00 and has touched a high and low of Rs. 3132.90 and Rs. 3104.10 respectively. So far 7536 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.
Last one week high and low of the scrip stood at Rs. 3132.90 and Rs. 3023.50 respectively. The current market cap of the company is Rs. 53040.53 crore.
The promoters holding in the company stood at 25.57% while Institutions and Non-Institutions held 43.50% and 30.93% respectively.
Dr. Reddys Laboratories’ subsidiary -- Promius Pharma has announced that ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US.
ZEMBRACE SymTouch is a prefilled, low-dose, ready to use, 2-step autoinjector containing 3mg of sumatriptan a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief in migraine.
Dr. Reddy's Laboratories, is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: